ArticleEuropean urology2023

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)].

Elizabeth R Plimack et al.PubMed ↗Publisher ↗

No numbers read from the abstract.